Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALLURION TECHNOLOGIES, INC.ALUR · Entity 8577 | Director | October 23, 2023 | October 25, 2023 |
| AMGEN INCAMGN · Entity 2832 | Director | August 07, 2026 | August 11, 2026 |
| INTEL CORPINTC · Entity 2799 | Director | March 28, 2025 | April 01, 2025 |
| Medtronic plcMDT · Entity 2888 | Director · Executive Chairman | October 15, 2020 | December 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALLURION TECHNOLOGIES, INC.
Report date October 23, 2023 · Filed October 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,235 |
Reported balance
After 2023-10-23 transaction · row 1
1 source rowRow 1 · 2023-10-23 · Grant · Acquired 45,235 · Balance 45,235 F1: The shares reported in this transaction represent an initial, one-time grant of Restricted Stock Units ("RSUs") issued pursuant to the Issuer's non-employee director compensation policy and the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in equal annual installments over three years from October 23, 2023, subject to the Reporting Person's continued service as a director of the Issuer on each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 710,228 |
Reported balance
Holding disclosure · report date 2023-10-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 710,228 F2: Shares held by Omar & Helen Ishrak Living Trust ("Ishrak Trust"). The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Ishrak Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,262,711 |
Reported balance
Holding disclosure · report date 2023-10-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,262,711 F3: The shares are held directly by Compute Health Sponsor LLC ("Compute Health"). The Reporting Person is a managing member of Compute Health and disclaims beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is a beneficial owner of the securities reported in this filing for purposes of Section 16 of the Exchange Act. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares reported in this transaction represent an initial, one-time grant of Restricted Stock Units ("RSUs") issued pursuant to the Issuer's non-employee director compensation policy and the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in equal annual installments over three years from October 23, 2023, subject to the Reporting Person's continued service as a director of the Issuer on each such vesting date.
F2: Shares held by Omar & Helen Ishrak Living Trust ("Ishrak Trust"). The Reporting Person disclaims Section 16 beneficial ownership of the securities held by the Ishrak Trust, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose.
F3: The shares are held directly by Compute Health Sponsor LLC ("Compute Health"). The Reporting Person is a managing member of Compute Health and disclaims beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is a beneficial owner of the securities reported in this filing for purposes of Section 16 of the Exchange Act.
AMGEN INC
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,485.9046 |
Reported balance
After 2026-08-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 85.1685 · Balance 7,485.9046 F1: These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
INTEL CORP
Report date March 28, 2025 · Filed April 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,838.215 |
Reported balance
After 2025-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-28 · Grant · Acquired 1,376.046 · Balance 5,838.215 F1: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock. F2: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each phantom stock unit represents the right to receive the cash value of one share of Intel common stock.
F2: Phantom stock units are payable in cash following termination of the reporting person's service on the board of directors.
Medtronic plc
Report date October 15, 2020 · Filed December 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Indirect2019 GRAT | 9,532 |
Reported balance
After 2020-10-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-10-15 · Gift · Disposed 8,650 · Balance 9,532 |
| Ordinary SharesSEC Table I · non-derivative | IndirectJoint Revocable Trust | 8,650 |
Reported balance
After 2020-10-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-10-15 · Gift · Acquired 8,650 · Balance 8,650 F1: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse and the reporting person are co-trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Ordinary SharesSEC Table I · non-derivative | Indirect2020 GRAT | 22,508 |
Reported balance
Holding disclosure · report date 2020-10-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 22,508 |
| Ordinary SharesSEC Table I · non-derivative | Direct | 568,982 |
Reported balance
Holding disclosure · report date 2020-10-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 568,982 F2: This balance increased by 2,050 shares due to exempt transactions such as dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse and the reporting person are co-trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: This balance increased by 2,050 shares due to exempt transactions such as dividend reinvestment.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Compute Health Acquisition Corp.
Report date August 01, 2023 · Filed August 03, 2023 · Amendment
Jointly reported with Compute Health Sponsor LLC, Nehme Jean, Fink Joshua A
Section 16 reporting ended · disclosed 2023-08-03. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2023-08-01 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-08-01 · Grant · Acquired 2,088,327 · Balance 2,088,327 F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F3: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein. Row 2 · 2023-08-01 · Disposition to issuer · Disposed 161,379 · Balance 1,926,948 F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F4: Pursuant to the terms of that certain Contribution Agreement, dated as of May 2, 2023, by and between the issuer and the Sponsor, 161,379 shares of Class A Common Stock held by the Sponsor were contributed to the capital of the issuer. F3: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein. Row 3 · 2023-08-01 · Disposition to issuer · Disposed 1,926,948 · Balance 0 F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F5: Pursuant to the terms of the Business Combination Agreement, each of the 1,926,948 shares of Class A Common Stock held by the Sponsor were canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value. F3: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-01 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2023-08-01 · Disposition to issuer · Disposed 21,442,500 · Balance 0 F6: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date. F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination"). F2: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination. F3: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects transactions in connection with that certain Business Combination Agreement (the "Business Combination Agreement"), dated as of February 9, 2023 and amended as of May 2, 2023, by and among the issuer, Allurion Technologies Opco, Inc. (f/k/a Allurion Technologies, Inc.) ("Allurion"), Allurion Technologies, Inc. (f/k/a Allurion Technologies Holdings, Inc.) ("Pubco") and the other parties thereto (the "Business Combination").
F2: Reflects the conversion of the issuer's Class B common stock, par value $0.0001 ("Class B Common Stock"), and 12,833,333 warrants acquired from the issuer in connection with the issuer's initial public offering into 2,088,327 shares of the issuer's Class A common stock, par value $0.0001 ("Class A Common Stock"), pursuant to the terms of that certain Sponsor Support Agreement, dated as of February 9, 2023, entered into by and among the issuer, Compute Health Sponsor LLC (the "Sponsor"), Allurion, Pubco and the other parties thereto, which was entered into in connection with the Business Combination.
F3: These securities are held in the name of the Sponsor, which is managed by its managing members, Omar Ishrak, Jean Nehme and Joshua Fink. Each of the Reporting Persons may be deemed a beneficial owner of securities held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such securities except to the extent of its respective pecuniary interest therein.
F4: Pursuant to the terms of that certain Contribution Agreement, dated as of May 2, 2023, by and between the issuer and the Sponsor, 161,379 shares of Class A Common Stock held by the Sponsor were contributed to the capital of the issuer.
F5: Pursuant to the terms of the Business Combination Agreement, each of the 1,926,948 shares of Class A Common Stock held by the Sponsor were canceled and converted into the right to receive 1.420455 shares of Pubco common stock, $0.0001 par value.
F6: As described in the issuer's registration statement on Form S-1 (File No. 333-252245) under the heading "Description of Securities--Founder Shares," the shares of Class B Common Stock were to automatically convert into shares of Class A Common Stock at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2020 Filed Dec 11, 2020 22:27 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 8,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-031212 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · 2019 GRAT Disclosed balance after: 9,532 Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 22:38 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026951 · form4.xml · nonDerivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,932 Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 22:38 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026951 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 GRAT Disclosed balance after: 0 Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 22:38 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 763 | $108.40 | $82,709.20 |
DisclosureSEC source: 0001127602-20-026951 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,032 F1 · price: The price in Column 4 is a weighted average price and has been rounded to two decimals. The share were sold in multiple transactions at prices ranging from $108.395 to $108.397, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 159,318 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022896 · form4.xml · derivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,318 Underlying: Ordinary Shares · 159,318 shares Expires 2030-08-03 F1 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 21:37 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 26,082 | $96.48 | $2,516,391.36 |
DisclosureSEC source: 0001127602-20-022589 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,795 F1 · balance_after: This balance increased by 2,888 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:31 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 22,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-021037 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · 2020 GRAT Disclosed balance after: 22,508 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:31 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 22,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-021037 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,989 F1 · balance_after: This balance increased by 2,307 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:45 UTC | INTEL CORP INTC · Entity 2799 | GrantRestricted Stock Units · Derivative | 3,721 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-016961 · form4.xml · derivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,721 Underlying: Common Stock · 3,721 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) and the date of the 2021 Annual Stockholders' Meeting. F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the first anniversary of the grant date (or next business date, if applicable) and the date of the 2021 Annual Stockholders' Meeting. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:45 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionRestricted Stock Units · Derivative | 4,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-016961 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the 1st anniversary of the grant date (or next business date, if applicable) and the date of the 2020 Annual Stockholders' Meeting. F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the 1st anniversary of the grant date (or next business date, if applicable) and the date of the 2020 Annual Stockholders' Meeting. Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:45 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 4,259 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-016961 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:24 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionPerformance-based Restricted Stock Units · Derivative | 2,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009507 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance-based Restricted Stock Unit (RSU) represents the right to receive, following vesting, up to 200% of one share of Intel common stock. The number of shares of Intel common stock acquired upon vesting of the performance-based RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on February 1, 2017 and ending on the third anniversary of February 1, 2017, unless that date falls on a date that the NASDAQ Stock Market is closed, in which case the next business date that the NASDAQ Stock Market is open shall apply. F1 · price: Each performance-based Restricted Stock Unit (RSU) represents the right to receive, following vesting, up to 200% of one share of Intel common stock. The number of shares of Intel common stock acquired upon vesting of the performance-based RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on February 1, 2017 and ending on the third anniversary of February 1, 2017, unless that date falls on a date that the NASDAQ Stock Market is closed, in which case the next business date that the NASDAQ Stock Market is open shall apply. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the performance-based RSU, each performance-based RSU vests and converts into no more than 200% of one share of Intel common stock three years and one month after February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the performance-based RSU, each performance-based RSU vests and converts into no more than 200% of one share of Intel common stock three years and one month after February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. F3 · derivative.underlying_shares: The total number of shares of Common Stock received upon achievement of the pre-established performance metrics was 1,819 (or 67.452% of the target number of performance-based RSUs granted), as reported in Table I. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:24 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 1,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-009507 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance-based Restricted Stock Unit (RSU) represents the right to receive, following vesting, up to 200% of one share of Intel common stock. The number of shares of Intel common stock acquired upon vesting of the performance-based RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on February 1, 2017 and ending on the third anniversary of February 1, 2017, unless that date falls on a date that the NASDAQ Stock Market is closed, in which case the next business date that the NASDAQ Stock Market is open shall apply. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 13:56 UTC | Medtronic plc MDT · Entity 2888 | PurchaseOrdinary Shares | 8,771 | $113.68 | $997,087.28 |
DisclosureSEC source: 0001127602-20-007086 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,190 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $113.65 to $113.70, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnote to this Form 4. F2 · balance_after: This balance increased by 1,994 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 00:06 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionRestricted Stock Units · Derivative | 845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-003273 · form4.xml · derivative · entry 4 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 845 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 00:06 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-003273 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. Read SEC document |
| January 30, 2020 Filed Feb 4, 2020 00:06 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionRestricted Stock Units · Derivative | 810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-003273 · form4.xml · derivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810 Underlying: Common Stock · 810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| January 30, 2020 Filed Feb 4, 2020 00:06 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-003273 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of Intel Corporation common stock. Read SEC document |
| December 03, 2019 Filed Dec 12, 2019 22:44 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 18,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034887 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2019 GRAT Disclosed balance after: 18,182 Read SEC document |
| December 03, 2019 Filed Dec 12, 2019 22:44 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 18,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-034887 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,425 F1 · balance_after: This balance increased by 2,184 shares due to exempt transactions such as dividend reinvestment. F2 · balance_after: Includes 7,615 shares previously reported as owned indirectly through the 2017 GRAT. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:22 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030330 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,808 Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:22 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030330 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 GRAT Disclosed balance after: 5,900 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 22:25 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 24,894 | $102.37 | $2,548,398.78 |
DisclosureSEC source: 0001127602-19-025931 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,708 Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:53 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 301,440 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001127602-19-025554 · form4.xml · derivative · entry 4 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,440 Underlying: Ordinary Shares · 301,440 shares Expires 2029-07-29 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 21:53 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 45,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-025554 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,602 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. F2 · balance_after: This balance increased by 7,686 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| May 16, 2019 Filed May 20, 2019 22:34 UTC | INTEL CORP INTC · Entity 2799 | GrantRestricted Stock Units · Derivative | 4,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019215 · form4.xml · derivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,259 Underlying: Common Stock · 4,259 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the 1st anniversary of the grant date (or next business date, if applicable) and the date of the 2020 Annual Stockholders' Meeting. F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the award, 100% of the RSUs vest and convert into common stock on the earlier of the 1st anniversary of the grant date (or next business date, if applicable) and the date of the 2020 Annual Stockholders' Meeting. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:14 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionRestricted Stock Units · Derivative | 844 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-004053 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845 Underlying: Common Stock · 844 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:14 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 844 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-004053 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:47 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionRestricted Stock Units · Derivative | 811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-003392 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,620 Underlying: Common Stock · 811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F2 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. F2 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 21:47 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-003392 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. Read SEC document |
| January 09, 2019 Filed Jan 9, 2019 17:27 UTC | Medtronic plc MDT · Entity 2888 | PurchaseOrdinary Shares | 12,000 | $84.05 | $1,008,540.00 |
DisclosureSEC source: 0001127602-19-001695 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,722 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $83.5 to $84.77, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnote to this Form 4. F2 · balance_after: This balance increased by 2,326 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 22:06 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027799 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 GRAT Disclosed balance after: 10,000 Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 22:06 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027799 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,396 Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:35 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 4,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027247 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,396 Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 20:35 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 4,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027247 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · GRAT Disclosed balance after: 7,615 Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 20:32 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 27,010 | $90.48 | $2,443,864.80 |
DisclosureSEC source: 0001127602-18-024845 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,816 Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:48 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 305,018 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001127602-18-024241 · form4.xml · derivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,018 Underlying: Ordinary Shares · 305,018 shares Expires 2028-07-30 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 19:48 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 50,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024241 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,826 F1 · security: This balance increased by 10,213 shares due to exempt transactions such as dividend reinvestment. F2 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2021 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:51 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionRestricted Stock Units · Derivative | 845 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004159 · form4.xml · derivative · entry 4 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,689 Underlying: Common Stock · 845 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F6 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. F6 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of February 1, 2017, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:51 UTC | INTEL CORP INTC · Entity 2799 | Exercise / conversionCommon Stock | 845 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004159 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired on the vesting of restricted stock units. Read SEC document |
| January 30, 2018 Filed Feb 6, 2018 01:51 UTC | INTEL CORP INTC · Entity 2799 | GrantRestricted Stock Units · Derivative | 2,431 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004159 · form4.xml · derivative · entry 3 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,431 Underlying: Common Stock · 2,431 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of Intel Corporation common stock. F5 · derivative.exercise_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited under the terms of the RSU, 33 1/3% of the awards vest and convert into common stock on each anniversary of the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| January 30, 2018 Filed Feb 6, 2018 01:51 UTC | INTEL CORP INTC · Entity 2799 | GrantPerformance-based Restricted Stock Units · Derivative | 2,102 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-004159 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,102 Underlying: Common Stock · 2,102 shares Expires not disclosed F2 · derivative.exercise_price: Each performance-based Restricted Stock Unit (RSU) represents the right to receive, following vesting, up to 200% of one share of Intel common stock. The number of shares of Intel common stock acquired upon vesting of the performance-based RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, over a three-year performance period beginning on the grant date and ending on the third anniversary of the grant date, unless that date falls on a date that the NASDAQ Stock Market is closed, in which case the next business date that the NASDAQ Stock Market is open shall apply. F3 · derivative.exercise_date: Unless earlier forfeited under the terms of the performance-based RSU, each performance-based RSU vests and converts into no more than 200% of one share of Intel common stock three years and one month after the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. F3 · derivative.expiration_date: Unless earlier forfeited under the terms of the performance-based RSU, each performance-based RSU vests and converts into no more than 200% of one share of Intel common stock three years and one month after the grant date, unless that date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 23:11 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $38.81 | $0.00 |
DisclosureSEC source: 0001127602-17-027649 · form4.xml · derivative · entry 4 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,338 Underlying: Ordinary Shares · 100,000 shares Expires 2022-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option to purchase 290,338 New Medtronic ordinary shares for $38.81 per share, which was partially vested at the effective time of the Merger, was received in the Merger and represents the conversion of 290,338 Medtronic common stock shares for $38.81 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 23:11 UTC | Medtronic plc MDT · Entity 2888 | SaleOrdinary Shares | 140,407 | $81.63 | $11,461,423.41 |
DisclosureSEC source: 0001127602-17-027649 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,096 F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.464 to $81.941, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 23:11 UTC | Medtronic plc MDT · Entity 2888 | Exercise / conversionOrdinary Shares | 100,000 | $38.81 | $3,881,000.00 |
DisclosureSEC source: 0001127602-17-027649 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:01 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026511 · form4.xml · nonDerivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · GRAT Disclosed balance after: 12,195 Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:01 UTC | Medtronic plc MDT · Entity 2888 | GiftOrdinary Shares | 12,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026511 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,503 Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:03 UTC | Medtronic plc MDT · Entity 2888 | GrantStock Option (Right to Buy) · Derivative | 214,363 | $0.00 Strike: $83.97 | $0.00 |
DisclosureSEC source: 0001127602-17-024714 · form4.xml · derivative · entry 2 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,363 Underlying: Ordinary Shares · 214,363 shares Expires 2027-07-31 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:03 UTC | Medtronic plc MDT · Entity 2888 | GrantOrdinary Shares | 53,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024714 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,698 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share growth during the 36 month period ending on the last day of the Company's fiscal year 2020 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:38 UTC | Medtronic plc MDT · Entity 2888 | Tax withholdingOrdinary Shares | 28,522 | $84.29 | $2,404,119.38 |
DisclosureSEC source: 0001127602-17-024467 · form4.xml · nonDerivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,107 F1 · balance_after: This balance increased by 5013 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.